M. Turner

27.2k total citations · 1 hit paper
323 papers, 7.5k citations indexed

About

M. Turner is a scholar working on Pediatrics, Perinatology and Child Health, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, M. Turner has authored 323 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Pediatrics, Perinatology and Child Health, 77 papers in Pulmonary and Respiratory Medicine and 43 papers in Public Health, Environmental and Occupational Health. Recurrent topics in M. Turner's work include Pharmaceutical studies and practices (91 papers), Neonatal Respiratory Health Research (64 papers) and Antibiotics Pharmacokinetics and Efficacy (25 papers). M. Turner is often cited by papers focused on Pharmaceutical studies and practices (91 papers), Neonatal Respiratory Health Research (64 papers) and Antibiotics Pharmacokinetics and Efficacy (25 papers). M. Turner collaborates with scholars based in United Kingdom, United States and Netherlands. M. Turner's co-authors include Thomas Leddy, Anthony J Nunn, Matthew Peak, Siobhan Quenby, Josephine Drury, Munir Pirmohamed, Susan Greenwood, Colin P. Sibley, Roger Mulder and Mike Sharland and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Oncology.

In The Last Decade

M. Turner

298 papers receiving 7.0k citations

Hit Papers

More Than Cool Reason: A ... 1990 2026 2002 2014 1990 250 500 750 1000

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
M. Turner 2.7k 1.2k 909 865 824 323 7.5k
Grace Chang 1.9k 0.7× 339 0.3× 1.2k 1.3× 752 0.9× 180 0.2× 169 6.8k
Εvangelos Εvangelou 647 0.2× 1.1k 0.9× 1.4k 1.5× 451 0.5× 349 0.4× 160 11.5k
Susan M. Sereika 1.0k 0.4× 1.8k 1.6× 2.4k 2.6× 405 0.5× 689 0.8× 414 13.0k
Thomas R. Einarson 2.8k 1.0× 592 0.5× 4.4k 4.8× 1.3k 1.5× 390 0.5× 239 13.7k
Kar Keung Cheng 1.6k 0.6× 1.5k 1.3× 2.3k 2.5× 453 0.5× 543 0.7× 401 11.8k
Maurizio Bonati 2.2k 0.8× 687 0.6× 963 1.1× 243 0.3× 148 0.2× 326 7.4k
Jae Il Shin 628 0.2× 1.7k 1.4× 1.3k 1.5× 302 0.3× 684 0.8× 547 14.8k
Anoshirvan Kazemnejad 983 0.4× 429 0.4× 1.5k 1.7× 493 0.6× 189 0.2× 612 7.3k
Justine Shults 1.5k 0.5× 1.4k 1.2× 2.3k 2.5× 308 0.4× 174 0.2× 313 11.8k
Rino Bellocco 645 0.2× 1.0k 0.9× 2.4k 2.6× 390 0.5× 505 0.6× 224 11.1k

Countries citing papers authored by M. Turner

Since Specialization
Citations

This map shows the geographic impact of M. Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Turner more than expected).

Fields of papers citing papers by M. Turner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Turner. The network helps show where M. Turner may publish in the future.

Co-authorship network of co-authors of M. Turner

This figure shows the co-authorship network connecting the top 25 collaborators of M. Turner. A scholar is included among the top collaborators of M. Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Turner. M. Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goodfellow, Laura, et al.. (2024). Preterm prelabour rupture of membranes before 23 weeks’ gestation: prospective observational study. SHILAP Revista de lepidopterología. 3(1). e000729–e000729. 5 indexed citations
2.
Price, Angie, Collin A. Hovinga, Thierry Lacaze‐Masmonteil, et al.. (2024). Harmonizing Quality Improvement Metrics Across Global Trial Networks to Advance Paediatric Clinical Trials Delivery. Therapeutic Innovation & Regulatory Science. 58(5). 953–964. 2 indexed citations
3.
Sharp, Andrew, Christine Cornforth, Richard Jackson, et al.. (2024). The efficacy of sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction: the STRIDER RCT. SHILAP Revista de lepidopterología. 1–61. 1 indexed citations
5.
Barker, Charlotte, Karin Kipper, D Lonsdale, et al.. (2023). The Neonatal and Paediatric Pharmacokinetics of Antimicrobials study (NAPPA): investigating amoxicillin, benzylpenicillin, flucloxacillin and piperacillin pharmacokinetics from birth to adolescence. Journal of Antimicrobial Chemotherapy. 78(9). 2148–2161. 5 indexed citations
6.
Lutsar, Irja, Begonya Nafría, Stefanie Breitenstein, et al.. (2022). Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children. Clinical and Translational Science. 16(3). 478–488. 6 indexed citations
7.
Litalien, Catherine, et al.. (2022). From paediatric formulations development to access: Advances made and remaining challenges. British Journal of Clinical Pharmacology. 88(10). 4349–4383. 14 indexed citations
8.
Salamat‐Miller, Nazila, M. Turner, Amey Bandekar, et al.. (2022). Assessment of compatibility of rhIGF-1/rhIGFBP-3 with neonatal intravenous medications. World Journal of Pediatrics. 19(1). 58–67.
9.
Preston, Jennifer, et al.. (2022). Developing a More Tailored Approach to Patient and Public Involvement with Children and Families in Pediatric Clinical Research: Lessons Learned. Therapeutic Innovation & Regulatory Science. 56(6). 948–963. 17 indexed citations
10.
Duncan, Jennifer C, Louise Bracken, Anthony J Nunn, Matthew Peak, & M. Turner. (2022). Development and evaluation of an assessment of the age-appropriateness/inappropriateness of formulations used in children. International Journal of Clinical Pharmacy. 44(6). 1394–1405. 2 indexed citations
11.
Smits, Anne, Pieter Annaert, Giacomo Cavallaro, et al.. (2021). Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper. British Journal of Clinical Pharmacology. 88(12). 4965–4984. 30 indexed citations
12.
Salamat‐Miller, Nazila, Christopher McPherson, Paul A. Salinas, et al.. (2021). Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates. Journal of Pharmaceutical Sciences. 111(5). 1486–1496. 3 indexed citations
14.
Sharp, Andrew, Richard Jackson, Christine Cornforth, et al.. (2019). A prediction model for short-term neonatal outcomes in severe early-onset fetal growth restriction. European Journal of Obstetrics & Gynecology and Reproductive Biology. 241. 109–118. 27 indexed citations
16.
Lima, Elisângela da Costa, et al.. (2018). Suspected adverse drug reactions reported for Brazilian children: cross-sectional study. Jornal de Pediatria. 95(6). 682–688. 14 indexed citations
17.
Morgan, Colin, et al.. (2013). Postnatal Head Growth in Preterm Infants: A Randomized Controlled Parenteral Nutrition Study. PEDIATRICS. 133(1). e120–e128. 131 indexed citations
18.
Richey, Roberta, Utpal Shah, Matthew Peak, et al.. (2013). Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidence. BMC Pediatrics. 13(1). 81–81. 110 indexed citations
19.
Turner, M.. (2003). Author's reply. The British Journal of Psychiatry. 183(6). 565–565. 1 indexed citations
20.
Turner, M., et al.. (2002). Intravenous long-lines in children with cystic fibrosis: a multidisciplinary approach.. PubMed Central. 95 Suppl 41. 11–21. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026